by Elena Iemma | Feb 23, 2024 | Blog
ISPRI for Bi-Specifics? Yes, we Can! In With the New! At this point in our evolution as a company, we can affirm that change is good! As promised, EpiVax 2.0 is emerging in 2024, with new products and new leaders! First, say hello to our...
by Elena Iemma | Jan 23, 2024 | Blog
Where will we meet you in 2024? It’s Post-Pandemic and we’re back on the road traveling to the 4 corners of the Earth. Where will we get to see you? Here’s a list of upcoming conferences and events, and because … what’s travel without...
by Elena Iemma | Dec 23, 2023 | Blog
FDA Request for “Integrated Summary of Immunogenicity” So much news to share! EpiVax Delivers! As promised, EpiVax 2.0 will be arriving in 2024, our 26th year, along with new team members and new plans to expand the range of services offered. Here...
by Elena Iemma | Dec 20, 2023 | News
PROVIDENCE, RI, December 20, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for immunogenicity risk assessment of...
by Elena Iemma | Nov 20, 2023 | News
EpiVax CEO Annie De Groot was one of three plenary session speakers at a recent international forum on vaccines organized by Joon Rhee. Her topic was ‘Better, Safer, and Personalized Vaccines will Result from Human + Artificial Intelligence’. Other speakers...
